California Gov. Gavin Newsom announced Monday, April 21, 2025, that the state will sell naloxone, the overdose-reversal medicine, to any resident at a steep discount. (Cal Matters File/Juliana Yamada)

- California is making progress in curbing fentanyl-related deaths.
- However, opioid overdoses continue to kill thousands of people every year.
- Naloxone is available online for $24 from the state for a two-pack, roughly half the market price.
Share
Getting your Trinity Audio player ready...
|
This story was originally published by CalMatters. Sign up for their newsletters.
Any Californian can purchase naloxone, an opioid overdose reversal medication, directly from the state at a discounted price, Gov. Gavin Newsom’s office announced Monday.
The medication is available online for $24 for a two-pack of the nasal spray, roughly half the market price of the drug. Previously, the discount was available only to government organizations and businesses.
“Life-saving medications shouldn’t come with a life-altering price tag. CalRx is about making essential drugs like naloxone affordable and accessible for all — not the privileged few,” Newsom said in a statement. CalRx is a Newsom initiative to bring down the cost of prescription drugs.
Opioids Killed 8,900 Californians Last Year
California has spent more than $1 billion fighting the opioid epidemic, which killed more than 8,900 people last year, according to preliminary data from the state health department. That represents a 13% increase in deaths from 2023.
The Naloxone Distribution Project and Access Initiative is part of the strategy to stop overdoses, which began spiking in 2019 as fentanyl, a highly potent synthetic opioid, infused the market. The rate of fentanyl-related overdose deaths began declining last year, according to state data.
More than 6 million naloxone kits have been distributed to local governments and organizations since 2018, according to state data. About 355,000 overdoses have been reversed.
In 2024, Newsom’s office announced a new supplier for the state initiative, Amneal Pharmaceuticals, which agreed to sell the steeply discounted drug to California. Days prior, Attorney General Rob Bonta announced a $273-million multistate settlement with the New Jersey-based company over its alleged failure to report suspicious opioid orders that contributed to the country’s epidemic.
“By getting this lower price, we are making the financial savings and able to use our dollars to buy more product, which of course is ultimately very much about saving lives,” said Elizabeth Landsberg, director of the Department of Health Care Access and Information, last year.
Related Story: Fresno County’s First Fentanyl Murder Trial Ends in Guilty Verdict
Naloxone is one of two current efforts by the state to make generic drugs more affordable under Newsom’s effort to lower the costs of pharmaceuticals. California has a $50-million contract to manufacture generic insulins for CalRx. That project is more than a year behind schedule.
Supported by the California Health Care Foundation (CHCF), which works to ensure that people have access to the care they need, when they need it, at a price they can afford. Visit www.chcf.org to learn more.
This article was originally published on CalMatters and was republished under the Creative Commons Attribution-NonCommercial-NoDerivatives license.
RELATED TOPICS:
My Friend Joseph Castro, Former Fresno State President and CSU Chancellor, Is Receiving Hospice Care
9 hours ago
More Americans Applying for Refugee Status in Canada, Data Shows
10 hours ago
US Supreme Court Lets Trump Cut Diversity-Related NIH Grants
10 hours ago
Judge Rules Alina Habba Was Unlawfully Appointed as US Attorney in New Jersey
11 hours ago
Fresno Man with Prior Felonies Charged with Meth, Fentanyl, and Ammunition
12 hours ago
Fresno Goes to Court to Fight Trump Rule Stripping Grants Over Woke Language
12 hours ago

My Friend Joseph Castro, Former Fresno State President and CSU Chancellor, Is Receiving Hospice Care

More Americans Applying for Refugee Status in Canada, Data Shows

US Supreme Court Lets Trump Cut Diversity-Related NIH Grants
